1
compared to the results of a recent European study. Forty-eight loci reached genome-wide significance 1 (Methods section); of them, nine loci were previously unreported ( Table 1 , Supplementary Table 4 , 2 Supplementary Fig. 5 , Supplementary Data Set 1,2). A novel locus on 9q31 habours ABCA1, a critical 3 gene for high-density lipoprotein cholesterol (HDLC) homeostasis, whose disruption causes a severe 4 deficiency in serum HDLC 25 . The lead variant rs35093463 is located in the intron of ABCA1. The higher 5 frequency of this variant in Japanese (MAF 36%) compared to Europeans (MAF 5%) might have 6
contributed to the discovery of this loci in this study. Besides, we detected a relatively strong signal [MAF 7 = 1.0%, odds ratio for CAD development (OR CAD ) =1.61 and its 95% confidence interval (95%CI) = 1.46 8 -1.78, P = 2.3 × 10 -21 ] on the chromosome 17q25, where the lead variant rs112735431 causes a 9 nonsynonymous substitution in the RNF213 gene. rs112735431 is also known as an established 10 susceptibility variant for moyamoya disease 26 , which is a rare cerebrovascular disease with abnormal 11 vascular formation or obstruction. Since this variant is highly specific to the East Asian population, 12
previous European studies could not assess its importance in CAD. 13
Very rare, high-impact signals in the genome-wide significant loci and their pleiotropy 14
To detect additional CAD-associated signals independent of the lead variants among the genome-wide 15 significant loci, we performed conditional analysis for each locus of interest. This conditional analysis 16 revealed 25 additional independent signals (locus-wide P < 1.0 × 10 -5 ) in 48 genome-wide significant loci. 17
They included rare variants with a high impact on the development of CAD ( Fig. 1a , Supplementary Table  18 5). Of these genome-wide or locus-wide significant variants, we found one stop gain, five missense, and 19 one in-frame deletion variants. In particular, a stop-gain variants (rs879255211) in the LDLR gene showed 20 a dramatically high OR CAD [MAF = 0.038%, OR CAD (95% CI) = 4.97 (2.49 -9.93), P = 5.5 × 10 -6 ]. We 21 also found two missense variants in PCSK9 [rs151193009, MAF = 0.99%, OR CAD (95% CI) = 0.64 (0.57 -22 0.72), P = 1.21 × 10 -14 ; rs564427867, MAF = 1.1%, OR CAD (95% CI) = 1.31 (1.19 -1.44), P = 2.7 × 10 -8 ], 23 and one in APOB [rs13306206, MAF = 3.8%, OR CAD (95% CI) = 1.38 (1.31 -1.46), P = 4.8 × 10 -35 ] 24 surpassing genome-or locus-wide significance thresholds. 25
To explore the biological pathways in which these independent signals play roles in CAD development, we 26 performed association analyses for 34 clinical indices, including clinical measurements [body mass index 1 lipoprotein cholesterol (LDLC)] and lifestyles (cigarette smoking and alcohol drinking) in the BBJ dataset. 2
We found 121 significant associations (P < 0.05 / 2,482) in 29 phenotypes among the 34 tested 3 ( Supplementary Fig. 6 , Supplementary Table 6 ). The most frequent association was found between serum 4 TC and these variants. The CAD risk-increasing alleles of these variants are completely matched with the 5 TC increased allele (14/14, Fig. 1b ). Especially, rs879255211 showed a large impact on serum TC levels 6
[MAF = 0.038%, β TC-raw (standard error (SE)) = 74.6 (8.90) mg/dL per allele, P TC-adjusted = 1.4 × 10 -10 ] in 7 accordance with its large impact on CAD development. In addition, rs553577764, a rare intronic variant in 8 DOCK6 with a high OR CAD , also showed a large impact on serum TC levels [OR CAD (95% CI) = 3.08 9
(2.22 -4.26), P = 1.2 × 10 -11 , β TC-raw (SE) = 57.9 (4.30) mg/dL per allele, P TC-adjusted = 1.2 × 10 -21 ]. We 10 noted that this variant was in high LD (R 2 = 0.639) with rs746959386, which is a missense variant of 11 LDLR registered in the ClinVar database as "Likely pathogenic" for FH [MAF = 0.057%, OR CAD (95% CI) 12 = 3.11 (2.21 -4.37), P = 4.8 × 10 -11 , β TC-raw (SE) = 63.4 (4.48) mg/dL per allele, P TC-adjusted = 8.3 × 10 -21 , 13 Supplementary Table 7 ]. We also noted that a splicing variant of LDLR showed a nominal association with 14 CAD development [rs778408161, MAF = 0.074%, OR CAD (95% CI) = 2.15 (1.44 -3.21), P = 1.6 × 10 -4 ] 15 and a significant association with TC levels [β TC-raw (SE) = 43.9 (4.85) mg/dL per allele, P TC-adjusted = 2.5 × 16
The minor allele of rs151193009 in PCSK9 showed a protective effect against CAD development and a 18 negative effect on serum TC levels [β TC-raw (SE) = -24.3 (1.06) mg/dL per allele, P TC-adjusted = 2.3 × 10 -111 ]. 19
This variant results in the amino acid substitution, Arg93Cys, which decreases the affinity of PCSK9 for 20 LDLR 27 , and could have negative impacts on CAD development and TC levels. In contrast, the minor 21 allele for rs564427867 in PCSK9 showed an increased risk for CAD development and increased TC levels 22
[β TC-raw (SE) = 26.4 (1.06) mg/dL per allele, P TC-adjusted = 6.0 × 10 -91 ]. rs13306206 is a missense variant of 23 APOB, and its minor allele increased the risk of CAD development. In concordance, the risk allele of 24 rs13306206 was associated with an increased level of serum TC [β TC-raw (SE) = 19.9 (0.59) mg/dL per 25 allele, P TC-adjusted = 8.6 × 10 -155 ]. rs112735431, a missense variant of RNF213 that was described above, 26 showed a significant association with systolic blood pressure (SBP) [β SBP-raw (SE) = 2.48 (0.66) mmHg per coding variants including all of the abovementioned variants. We found that these variants were highly 1 specific to the East Asian population and not found in the European population. Notably, rs879255211 and 2 rs746959386 are not found even in the East Asian population in the 1000 Genomes Project 23 or gnomAD 3 dataset 28 . 4
Individuals with rare coding variants in monogenic genes for FH showed the worse cardiovascular 5 outcome 6
Epidemiological studies have shown that patients with FH have premature myocardial infarctions and 7 worse outcomes because of recurrent ischemia 29 . However, the definition of FH in previous 8 epidemiological studies was mainly based on clinical criteria. To confirm the association between clinical 9 outcomes and deleterious variants in established FH genes, we assessed the association of the carrier status 10 of the variants detected in the current study (rs564427867 in PCSK9, MAF = 1.1%; rs13306206 in APOB, 11 MAF = 3.8%, and rs879255211, rs746959386, and rs778408161 in LDLR, MAF = 0.038%, 0.057%, and 12 0.074%, respectively) with clinical indicators. We found that these variants are significantly enriched in 13 the patients with acute coronary syndrome [ACS, defined as a composite of acute myocardial infarction 14 (AMI) and unstable angina] compared to those with stable angina pectoris (SAP) [OR ACS/SAP (95% CI) = 15 1.23 (1.14 -1.33) per allele. P = 1.2 × 10 -7 , Fig. 2a , Supplementary Fig. 7a ]; ACS tends to be associated 16 with a more aggressive clinical course than SAP. In addition, individuals with these variants developed 17 AMI at a younger age than non-carriers [effect size on onset age per allele (95% CI) = -1.52 (-2.06; -0.98), 18 P = 4.7 × 10 -8 , Fig. 2b ]. In concordance with these results, as illustrated in Fig. 2c , carriers of these 19 variants showed significantly increased cardiovascular mortality than non-carriers [adjusted hazard ratio 20 (HR) = 1.16, 95% CI = 1.07 -1.27, P = 3.5 × 10 -4 , Supplementary Fig. 7b ). 21
Transethnic meta-analysis identified 37 novel CAD-associated loci 22
To increase the power for detecting further associations with CAD, we conducted a transethnic meta-23 analysis combining the current Japanese GWAS data and previously published data from two large-scale 24 CAD GWAS, CardiogramPlusC4D (C4D) and UK Biobank (UKBB), mainly involving subjects of 25
European descent ( Supplementary Fig. 1b ) 7,9 . To account for the ancestral heterogeneity in each study, we 26 applied the MANTRA algorithm in the analysis 30 . By combining all three datasets, there was a total of 121,234 CAD cases (BBJ: 25,892, C4D: 60,801, UKBB: 34,541) and 527,824 controls (BBJ: 142,336, 1 C4D: 123,504, UKBB: 261,984). A total of 4,804,024 SNPs was tested and 176 loci reached the genome-2 wide significance threshold [log 10 Bayes factor (BF) > 6, Fig. 3 , Supplementary Table 9 , Supplementary 3 Data Set 3,4] 31 . Forty-three of these loci were not previously reported (Table 2) , including six loci that we 4 detected in the current Japanese GWAS. In total, we found 46 previously unreported loci in the Japanese 5 GWAS and the transethnic meta-analysis. Among these loci, we found a novel association on chromosome 6 5q13, which harbours HMGCR encoding the late limiting enzyme in endogenous cholesterol synthesis, 3-7 hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This is the target enzyme of statins, the 8 most prevalent lipid lowering agents. The lead variant rs13354746 is located in 13kb upstream of HMGCR, 9 and the risk allele of this variant is highly associated with increased serum TC levels in the Japanese 10 population 32 . 11
Transethnic fine mapping of CAD-associated loci 12
For the fine mapping of the CAD-associated loci, we constructed credible sets for the genome-wide 13 significant loci detected in the transethnic meta-analysis. To assess the contribution of the transethnic 14 meta-analysis to the sizes of the credible sets, we compared the numbers of variants included in the 99% 15 credible sets derived from the transethnic meta-analysis (BBJ, C4D, and UKBB) and the meta-analysis of 16 the two previous European studies (C4D and UKBB, Supplementary Table 10 ). The sizes of the 99% 17 credible sets in the previously established loci derived from the transethnic meta-analysis were 18 significantly decreased compared to those from the European only analysis [Median number of variants 19 (1st-3rd quantile value) = 13.5 (5 -33.5) and 19 (6 -55.5), respectively, P = 8.7 × 10 -9 , paired Wilcoxon 20 rank-sum test, Supplementary Fig. 8 ]. We found 28 and 55 lead variants with a posterior probability of 21 association (PPA) greater than 80% and 50%, respectively ( Supplementary Table 11 ), including four 22 coding variants (rs11556924 in ZC3HC1, rs11601507 in TRIM5, rs3741380 in EHBP1L1, and rs1169288 23 in HNF1A). A previous study implicated three of these variants (rs11556924, rs11601507, and rs3741380) 24 as a causal variant for each locus 9 . rs1169288, a non-synonymous variant in HNF1A (Ile27Leu), which 25 encodes a crucial transcription factor highly expressed in the liver and intestine 33 , was also previously 26 implicated in cholesterol homeostasis and glucose tolerance 32,34 , and was predicted to be highly protein
Shared allelic effects in the transethnic meta-analysis, and derivation of the transethnic PRS 1
To assess the heterogeneity of allelic effects on CAD development among the studies, we next compared 2 the alternate allele frequency (AAF) and β CAD between the Japanese and two European studies 3 ( Supplementary Fig. 9 ). We observed considerably different allele frequencies between the Japanese and 4
European studies for the 176 lead variants detected in the transethnic meta-analysis. Nevertheless, we 5 found a significant positive correlation and concordant allelic effects of these variants (Spearman's ρ BBJ-6 C4D = 0.81, P BBJ-C4D = 6.2 × 10 -42 ; ρ BBJ-UKBB = 0.79, P BBJ-UKBB = 8.0 × 10 -39 . directional consistencies were 7 95.5% for BBJ vs. C4D and 94.9% for BBJ vs. UKBB). 8
For further exploration of allelic effect consistency, we compared the allelic effect directions of 9 the variants with various significances ( Supplementary Fig. 10 ). We observed strong correlations of allelic 10 effect direction in the variants with genome-wide significance (concordant rate of allelic effect was 95.9% 11
for variants with P fixed-effect < 5 × 10 -8 , 100% for P random-effect < 5 × 10 -8 ) as mentioned above. Moreover, we 12 found significant concordance of allelic effect direction in variants even with nominal significance (82.0% 13
for P fixed-effect < 0.05, 93.7% for P random-effect < 0.05). In addition, we noted that the random-effect model 14 consistently gives better estimates for variants with shared allelic effect across these P-value thresholds. 15
The transethnic meta-analysis substantially increased the number of significant associations and 16 suggested a shared allelic effect among ethnicities. These results indicate that transethnic meta-analysis 17 could improve the performance of a PRS. To determine the best PRS under such circumstances, we 18 derived the PRS exhaustively from all combinations of summary statistics, reference LD structure, and 19 parameters for derivation. As a result, the random-effects transethnic meta-analysis showed the best 20 performance [Nagelkerke's R 2 = 0.0776, the area under the receiver-operator curve (AUC) = 0.664, OR = 21 8.30, Supplementary Fig. 11 , Supplementary Table 12 ], in the independent Japanese case-control 22 validation cohort (1,827 cases, 9,172 controls). This transethnic CAD-PRS outperformed the previously 23 derived CAD-PRS from a European study 16 (Nagelkerke's R 2 = 0.0479, AUC = 0.628, OR = 3.70, P = 1.3 24 × 10 -6 vs. transethnic CAD-PRS) or the PRS derived from the current Japanese GWAS (Nagelkerke's R 2 = 25 0.0498, AUC = 0.634, OR = 4.24, P = 7.1 × 10 -7 , vs. transethnic CAD-PRS).
To determine the clinical pathways explaining the involvement of the CAD-PRS in CAD pathophysiology, 1 we assessed the correlation between the CAD-PRS and various phenotypes as denoted above. Among the 2 34 variables tested, significant correlations were observed between 13 clinical factors and CAD-PRS after 3 multiple-testing correction ( Fig. 4a , Supplementary Fig. 12 , Supplementary Fig. 13 , Supplementary Table  4 13). Most of the traditional CAD risk factors, including blood pressure and lipid or diabetic measurements, 5 showed significant correlations with the CAD-PRS. SBP showed the most significant positive correlation 6
[Spearman's ρ (95% CI) = 0.052 (0.042 -0.061), P = 1.9 × 10 -24 ], and HDLC showed the third most 7 significant, negative correlation as expected from its clinical consequence [ρ (95% CI) = -0.045 (-0.057; -8 0.033), P = 2.9 × 10 -13 ]. The CAD-PRS was also significantly correlated with inflammatory markers 9
[white blood cell count (WBC), ρ (95% CI) = 0.018 (0.008 -0.027), P = 3.2 × 10 -4 ], alcohol drinking [β 10 (95% CI) = -0.048 (-0.069; -0.027), P = 6.8 × 10 -6 ], and cigarette smoking [β (95% CI) = 0.040 (0.016 -11 0.065), P = 1.3 × 10 -3 ]. 12
CAD-PRS and cardiovascular mortality 13
Considering the strong correlation between the CAD-PRS and CAD risk factors (e.g., blood pressure, 14 serum lipid profiles), we hypothesized that CAD-PRS reflects the severity of the genetic background for 15 CAD development, and as a result, the individuals who have a high CAD-PRS will have a poor prognosis. 16
To test this hypothesis, we assessed the impact of the CAD-PRS on mortality in long-term follow-up data. Supplementary Table 14 ]. Of note, this association was highly specific to 21 circulatory diseases, and other causes of death were not associated with the CAD-PRS. We found 22 significant association between CAD-PRS and all-cause mortality [HR (95% CI) = 1.05 (1.02 -1.07), P = 23 3.4 × 10 -4 ], but, when we excluded ICD10-I disease from all-cause mortality, the significance was 24 diminished [HR (95% CI) = 1.02 (0.99 -1.05), P = 0.183]. Furthermore, we divided individuals who died 25 from ICD10-I into three sub-categories: ischemic heart disease (ICD-10 I21-I25), congestive heart failure 26 (1.08 -1.37), P = 1.8 × 10 -3 for congestive heart failure, HR (95% CI) = 1.06 (0.96 -1.16), P = 0.25 for 1 stroke, Fig. 4c , Supplementary Table 14) . 2
Genetic basis of CAD-PRS-associated traits 3
Finally, to assess the related loci of these CAD-PRS associated traits, we performed association analyses 4 for the 176 lead variants detected in the transethnic meta-analysis and the 13 CAD-PRS-associated traits in 5 the BBJ dataset. Ninety-seven variant-phenotype pairs showed Bonferroni-corrected significance (P < 6 0.05/2,288, Supplementary Fig. 15 , Supplementary Table 15 ). Serum TC level was the most frequently 7 associated trait (18 associations) and the directions of allelic effect (CAD-risk and TC-increasing) were 8 completely concordant (18/18) . To further characterize the relationships between the CAD-associated loci 9
and pleiotropic effects on CAD risk factors, we performed unsupervised clustering for the Z-value matrix 10 of these variants, revealing distinct functional clusters ( Supplementary Fig. 16 ). The loci with positive 11 impacts on serum TC or LDLC levels segregated in Cluster 1. This cluster contains well-characterized loci 12 associated with serum lipid profiles, exemplified by PCSK9, APOB, HMGCR, and LDLR. Cluster 2 13
harbours the loci associated with glycaemic traits. The loci in Cluster 3 positively impact on WBCs; the 14 9p21 (CDKN2B-AS1) locus is included in this cluster. The loci in cluster 4 positively impact serum 15 triglyceride levels and negatively impact HDLC levels; this cluster also contains APOA5 and LPL loci, 16
which are crucial genes for lipoprotein metabolism. Cluster 5 includes lead variants that affect BMI. 17
Cluster 6, the second largest cluster, contains loci associated with blood pressure. 18
Discussion 19
We performed a large-scale CAD GWAS in the Japanese population in combination with whole-genome 20 sequencing, transethnic meta-analysis, and analyses of various types of biobank-based datasets, including 21 clinical phenotypes and long-term follow-up data. In addition to discovering 46 novel loci, we confirmed 22 the clinical relevance of the CAD-PRS to survival prediction and its association with various CAD-23 associated phenotypes. 24
The use of a population-and disease-specific reference haplotypes improved the imputation found significant associations between a loss-of-function variant in LDLR and a high OR for CAD. This 1 variant was not even found in the large-scale sequencing database (gnomAD) that included a substantial 2 number of individuals of East Asian ancestry. In addition, such disease-relevant rare variants identified in 3 this study are highly population specific ( Supplementary table 8 ). These findings warrant further effort for 4 sequencing of diseased individuals in diverse populations to explore disease mechanisms and molecular 5 targets. Although the contribution of these rare and very rare variants to the total disease heritability is 6 small, accurate information on the effects of these variants is essential to provide better medical advice or 7 genetic counselling for the carriers. Therefore, continuous efforts should be devoted to research on the 8 behaviour and the impact of such rare variants in the population. 9
In addition to these population-specific rare variants, we found 176 genome-wide associated loci 10 for CAD including 43 novel loci in the transethnic meta-analysis. The allelic effects of these lead variants 11
showed almost the same directionality between our Japanese GWAS and previously reported European 12
GWAS. This result coincides with previous findings that allelic effects of complex diseases or traits are 13 shared between individuals of East Asian and European descent 19, 20 . Moreover, we observed that a large 14
proportion of variants with nominal significance showed directional consistency. This shared allelic effect 15 enabled us to derive a CAD-PRS from a transethnic meta-analysis for Japanese, which outperformed those 16 derived from either Japanese or European GWAS results. Recently, it was reported that a PRS derived 17 from a specific ethnic group could not achieve the same performance with other ethnic groups 39 . Before 18 the implementation of PRS in clinical practice or public health policies, it is essential to develop PRS that 19 are impartial and applicable to diverse populations. Therefore, it is crucial to develop a reliable method to 20
share GWAS results between different ethnic groups effectively. Our results indicate that a transethnic 21 meta-analysis could assist in the extrapolation of existing data that was obtained with a different ancestry. 22
In the phenome-wide analysis, we found significant dose-dependent relationships between the In the Informed consent was obtained from all participants in each study. Our study was approved by the 17 relevant ethical committees at each facility. 18
Whole-genome sequencing, quality control, and construction of reference panels. We sequenced 19 1,782 samples from patients with early-onset CAD (cases) and 3,148 controls. Whole-genome sequencing 20 was performed on the HiSeqX5 platform aiming at a 15 × depth, using 2 × 150-bp paired-end reads. All 21 case samples were obtained from the BBJ cohort (n = 1,782), and control samples were obtained from the 22 BBJ (n = 1,007) or Nagahama (n = 2,141) cohort. Sequenced data were processed using Picard and aligned 23 to the hs37d5 reference genome in the BBJ cohort and to hg19 in the Nagahama cohort using the Burrows-24
Wheeler algorithm. Genotypes of the samples were called individually in each centre using the 25
HaplotypeCaller according to Genome Analysis Toolkit best practice for germline SNPs and indels. Per-26 sample GVCF genotype data were merged and jointly called using GenotypeGVCFs. We defined genotype (GQ) < 20. We set these genotypes as missing and excluded variants with call rates < 90% before 1 variant quality score recalibration (VQSR). After VQSR filtering, sample quality control was performed 2 by excluding samples with excess heterozygosity, excess singletons, and closely related samples estimated 3 based on identity by states (PIHAT > 0.2). Principal component analysis restricted samples in the Japanese 4 mainland cluster. After excluding these samples, 1,781 CAD cases and 2,636 controls remained. Then 5 variant quality control was performed excluding variants (1) with more than 5% missing data, (2) with a 6
Hardy Weinberg equilibrium P-value < 1 × 10 -6 , (3) with an allele frequency difference in control samples 7 between data processing centres (BBJ and Nagahama cohort, Fisher's exact test P < 1 × 10 -6 ), (4) in the 8 low complexity region, and (5) overlapping with insertions or deletions. After these procedures, we 9 performed case control association analysis using genotypes in whole genome sequence data, and 10 confirmed that the variant quality was well controlled ( Supplementary Fig. 17 ). To construct the reference 11 panel, we excluded singletons from the quality-controlled whole-genome sequencing data, and then 12 haplotype phasing was performed using Eagle (v2.4.1) 43 . Phased VCFs were transformed into m3vcf 13 format using minimac3 (v2.0.1) 44 . For comparison purposes, we obtained genotypes from the 1000 14
Genomes Project phase 3 (version 5). We then constructed the reference panel under the same pipeline for 15 all subjects (n = 2,504) and for East Asian subjects (n = 504) separately. 16
Haplotype phasing and imputation of case-control samples. The subjects included in the GWAS were 17 genotyped using the HumanOmniExpressExome platform (Illumina) or in combination with 18
HumanOmniExpress and HumanExomeBeadChip (Illumina). For variant quality control, we excluded 19 variants with (1) call rates < 99%, (2) Hardy Weinberg Equilibrium P-values < 1.0 × 10 -6 , and (3) 20 heterozygous counts less than five. After exclusion of these variants, we performed pre-phasing using 21
Eagle. Phased haplotypes were imputed to the reference panels by minimac3 44 . For evaluation of the 22 imputation quality, we created a phased genotype dataset comprised only of the OmniExpress13 array, 23 imputed up to the 1KG EAS , 1KG ALL , and BBJ CAD panels. After imputation, we compared the imputed 24 dosage and genotypes directly determined by the exome array. Correlations were assessed by Pearson's 25 correlation coefficients. For all downstream analyses, we excluded variants with R 2 < 0.3. Genotyped or 26 imputed variants were annotated by ANNOVAR (Build 2017 Jul 7 45 ), or the ClinVar database downloaded 27
Phenotype. CAD was defined as a composite of stable angina, unstable angina, and myocardial infarction, 1 which were determined by a physician upon study inclusion. The demographic features of the case-control 2 cohort are provided in Supplementary Table 16 . The quantitative trait data were obtained from medical 3 records. Quantitative traits were normalized and adjusted as described below. Before normalization, we 4 excluded samples from patients younger than 18 years and using the phenotype-specific criteria provided 5
in Supplementary Table 17 . We then corrected the effect of medication as follows. For individuals taking 6 cholesterol-lowering drugs, TC and LDLC levels were corrected by dividing by 0.7 as previously 7 reported 46,47 . For individuals taking antihypertensive drugs, 15 mmHg was added to the SBP and 10 8 mmHg to the diastolic blood pressure readings 48 . We next constructed a linear model for these phenotypes 9 with sex, age, age 2 , the top 10 principal components and disease status. For WBC and C-reactive protein 10 (CRP), smoking status was also introduced to the model. Using these models, we computed the residuals 11 of the phenotype for each individual. The residuals were normalized by inverse-rank normalization and 12 used as continuous variables 49 . Samples with excess heterozygosity, excess missing genotypes, a non- GWAS. The case-control association analysis was performed by logistic regression, implemented in 17 PLINK2 50 . Sex, age, age 2 , and the top 10 principal components were included in the model as covariates. 18
We tested 19,707,525 variants with a minor allele frequency (MAF) ≥ 0.02% in case-control population, 19 because our reference panel contained almost ten thousand haplotypes and variants with minor allele 20 counts ≥ 2 (0.02%). The genome-wide significance threshold was set at P < 5 × 10 -8 for variants with MAF 21 ≥ 1%, and P < 3.93 × 10 -9 (0.05/12,710,563) for those with MAF < 1% (number of variants with MAF < 22 1% = 12,710,563). To define a locus, we created a set of genomic ranges adding 500 kb bilaterally for all 23 variants with genome-wide significance, and then merged overlapping ranges. In the MHC region 24 (chromosome 6: 25,000,000-35,000,000 bp), we added 1 Mb to the signal bilaterally. Previously reported 25 loci were also created in the same manner based on the curated top variants. Significant loci without 26 overlap and a lead variant not in LD (<0.10) in both the East Asian or European population with 27 previously reported loci were considered novel. LD was estimated using genotypes of the 1KG dataset. For quantitative traits, we performed linear regression analysis implemented in PLINK2 for normalized 1 phenotypes as described above. 2 LD score regression and heritability estimation. We performed LD score regression with ldsc software 3 to estimate bias from population stratification and explained heritability 24 . We used the 1KG EAS 4 population as the reference LD panel and included only variants present in HapMap3 SNPs. For the 5 calculation of liability scale heritability, we assumed that the CAD prevalence in the Japanese population 6 is 0.8% based on a Japanese government report published in 2009 (https://www.mhlw.go.jp/). 7
Stepwise conditional analysis. To identify statistically independent signals in the loci, we performed 8 sample-level stepwise conditional analysis for each genome-wide significant locus defined as denoted 9
above. In the first step, we added the dosage of the lead variant to the covariates and performed logistic 10 regression for all variants in the locus. If we found a locus-wide significant association (P < 1 × 10 -5 ), we 11
additionally introduced the dosage of the most significant variant to the covariates. This procedure was 12 repeated until none of the variants showed locus-wide significance. 13
Meta-analysis. We obtained summary statistics for the European CAD-GWAS from the website of the 14
CARDIoGRAM plus C4D consortiums (http://www.cardiogramplusc4d.org/data-downloads/) 7 and online 15 supplementation of a previous report (https://data.mendeley.com/datasets/2zdd47c94h/1) 9 . We aligned the 16 β and allele frequency to the alternate allele of hg19 and then merged only SNPs with an MAF ≥ 1% in all 17 the summary statistics. The transethnic meta-analysis was performed using MANTRA(v2) 30 and genome-18 wide significance was set at log 10 BF > 6 according to a previous simulation result 31 . We excluded log 10 19 BF for heterogeneity > 6. For PRS derivation, β and P-values were calculated by fixed-and random-effects 20 meta-analyses using METASOFT (v2) 51 . 21
Estimation of allelic concordance. To obtain LD-independent variant sets at various significance levels, 22
we performed P-value thresholding for each P-value threshold from the summary statistics obtained from 23 the fixed-effect transethnic meta-analysis and random-effect transethnic meta-analyses. For these variant 24 sets, we calculated the Pearson's correlation coefficient of the β between the European study and Japanese Credible set analysis. To construct sets of variants that likely include causal variants in each significant 1 locus identified by the transethnic meta-analysis, we performed a credible set analysis. For each genome-2 wide associated locus, we calculated the PPA (π) 52 for all variants as follows: 3 4 Here, λ denotes the BF for variant j, and k denotes all of the variants included in the locus. We listed the 5 variants in order of decreasing PPA, and then constructed the 99% credible set including variants from the 6 top PPA until the cumulative PPA reached 0.99. For comparison, we performed the European meta-7 analysis using the C4D and the UKBB datasets (referred to as the European analysis). 8
PRS.
We derived the PRS by the P-value thresholding (P/T) method using summary statistics from the 1) 9
the Japanese GWAS with MAF > 0.01, 2) the transethnic meta-analysis of the fixed-effect model, and 3) 10
the mixed-effect model. We used the P-value thresholds 1.0, 0.5, 0.1, 0.05, 0.01, 1× 10 -3 , 5 × 10 -4 , 5 × 10 -6 , 11 5 × 10 -8 , and R 2 thresholds 0.2, 0.4, 0.6, and 0.8. Pruning and thresholding procedure was performed by 12 PLINK software version 1.90b3.37. Individual risk scores were computed with derived weights in 13 independent case-control cohorts (case = 1,827, control = 9,172) by multiplying the genotype dosage and 14 corresponding weight using PLINK2 software. To assess the performance of the PRS, we calculated the 15 Nagelkerke's R 2 , the AUC values and OR using a logistic regression model adjusted by age and sex. OR and Welfare in Japan, and identified the cause of death according to ICD-10. The follow-up rate was 97% 25 and the median follow-up period was 7.7 years. We divided the cause of death based on ICD-10 classifications and excluded categories with fewer than 100 events. HRs and associated P-values were 1 calculated for genotype dosage or PRS by the proportional hazard model adjusting for sex, age, age 2 , top 2 10 principal components, and disease status. Analyses were performed with the R package survival, and 3 survival curves were estimated using the R package survminer with modification. 4 PRS associated phenotypes. For clinical evaluation of the CAD-PRS, we randomly split and withheld 1/3 5 of the control samples. Using the remaining control samples and all case samples, we re-performed the 6 Japanese GWAS, transethnic meta-analysis, and PRS derivation ( Supplementary Fig. 1c ). Using the 7 derived model, we calculated the PRS for the withheld control samples, and assessed relationships between 8 the CAD-PRS and clinical indices including 32 numerical clinical traits and two binary lifestyle traits (i.e., 9 cigarette smoking and alcohol drinking). For the numerical traits, we calculated Spearman's correlation 10 coefficients, associated confidence intervals, and P-values. For the binomial traits, we performed logistic 11 regression adjusted by sex, age, age 2 , top ten principal components, and disease status. We set the 12 significance threshold at P < 0.05/34. Supplementary Table 17 .
